Most of the known genetic risk for Alzheimer’s disease is explained by single-letter DNA changes found in genome-wide association studies. Large structural rearrangements, such as copy-number variants ...
Scientists might have happened upon a new Alzheimer’s pathology. In the July 29 Nature Neuroscience, researchers led by Vilhelm Bohr at the National Institutes of Health, Baltimore, and Paul Robbins ...
Microglia in human brain are descended from progenitor cells that arose in the embryonic yolk sac—but does this remain the case life-long? Two new papers argue that in late adulthood, these original ...
Not all astrocyte lipid droplets are created equal. In the August 19 Nature Communications, scientists led by Priyanka Narayan at the National Institutes of Health in Bethesda, Maryland, report that ...
The FDA has given the nod to two blood tests for Alzheimer’s disease. On August 20 they cleared C2N’s Precivity AD2 test. On August 24, they announced that Roche’s Elecsys p-tau217 passed muster. Both ...
Joint conference: 19th Biennial Meeting of the Asian-Pacific Society for Neurochemistry (APSN), the 6th Symposium of the Federation of Asian Oceanian Neuroscience Societies (FAONS), and the Annual ...
This Notice of Change announces the participation of the National Institute of Neurological Disorders and Stroke (NINDS) in the Notice of Funding Opportunity,"Bioengineering Research Grants (BRG) (R01 ...
ALSP, Inc. is developing a small molecule drug for Alzheimer's Disease. As an employee of this company, I have a financial interest in the success of it's drug.
Contact Information Hangyu Wu Gungzhou, China Professional Information ...
This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...
The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...
At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results